Please assess the completion status of the following clinical trial:

Trial Title: Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide written informed consent~* Chronic genotype 1 and/or 4 HCV infection~* Normal ECG~* Negative serum pregnancy test for female subjects~* Male subjects and female subjects of childbearing potential must agree to use contraception~* Able to comply with the dosing instructions for study drug and able to complete the study schedule of assessments, including all required post treatment visits~Exclusion Criteria:~* Serious or active medical or psychiatric illness~* HIV or hepatitis B viral (HBV) infection~* Stomach disorder that could interfere with the absorption of the study drug~* Treated with an anti-HCV medication in the last 30 days~* Any prior exposure to an HCV nonstructural protein (NS)5a-specific inhibitor~* Use of human granulocyte-macrophage colony-stimulating factor (GM-CSF), epoetin alfa or other therapeutic hematopoietic agents within 2 weeks of screening~* History of clinically significant medical condition associated with other chronic liver disease~* Active spontaneous bacterial peritonitis at screening~* Females who are breastfeeding~* Infection requiring systemic antibiotics~* Participated in a clinical study with an investigational drug or biologic within the last 30 days~* Active or history (last 6 months) of drug or alcohol abuse~* History of organ transplant other than liver, kidney, or corneal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A, Group 1 (12 wk): CPT Class B (7-9) (Type: EXPERIMENTAL): LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
- Cohort A, Group 1 (24 wk): CPT Class B (7-9) (Type: EXPERIMENTAL): LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
- Cohort A, Group 2 (12 wk): CPT Class C (10-12) (Type: EXPERIMENTAL): LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
- Cohort A, Group 2 (24 wk): CPT Class C (10-12) (Type: EXPERIMENTAL): LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
- Cohort B, Group 3 (12 wk): F0-F3 Fibrosis (Type: EXPERIMENTAL): LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3
- Cohort B, Group 3 (24 wk): F0-F3 Fibrosis (Type: EXPERIMENTAL): LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
- Cohort B, Group 4 (12 wk): CPT Class A (5-6) (Type: EXPERIMENTAL): LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
- Cohort B, Group 4 (24 wk): CPT Class A (5-6) (Type: EXPERIMENTAL): LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
- Cohort B, Group 5 (12 wk): CPT Class B (7-9) (Type: EXPERIMENTAL): LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
- Cohort B, Group 5 (24 wk): CPT Class B (7-9) (Type: EXPERIMENTAL): LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
- Cohort B, Group 6 (12 wk): CPT Class C (10-12) (Type: EXPERIMENTAL): LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
- Cohort B, Group 6 (24 wk): CPT Class C (10-12) (Type: EXPERIMENTAL): LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
- Cohort B, Group 7 (12 wk): FCH (Type: EXPERIMENTAL): LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
- Cohort B, Group 7 (24 wk): FCH (Type: EXPERIMENTAL): LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete